To improve the accuracy of tumor burden assessment, we are expanding this model to incorporate clinical PSA, testosterone, imaging data, histology data on AR and Cyp17 immunohistochemistry and genomic data on ctDNA, AR amplification and mutations in ctDNA. Here, AR is linked to neoplasm.